valproic acid has been researched along with Familial Spastic Paraparesis, Htlv-1-Associated in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conclude that long-term treatment with VPA is safe in HAM/TSP." | 2.76 | Safety of long-term treatment of HAM/TSP patients with valproic acid. ( Asquith, B; Bangham, C; Belrose, G; Boxus, M; Césaire, R; Gillet, N; Lezin, A; Olindo, S; Rodriguez, S; Signaté, A; Smadja, D; Verlaeten, O; Willems, L, 2011) |
| "Importantly, HTLV-1 does not cause ATLL through insertional mutagenesis." | 2.47 | [Virological aspects of HTLV-1 infection and new therapeutical concepts]. ( Mahieux, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afonso, PV | 1 |
| Mekaouche, M | 1 |
| Mortreux, F | 1 |
| Toulza, F | 1 |
| Moriceau, A | 1 |
| Wattel, E | 1 |
| Gessain, A | 1 |
| Bangham, CR | 1 |
| Dubreuil, G | 1 |
| Plumelle, Y | 1 |
| Hermine, O | 1 |
| Estaquier, J | 1 |
| Mahieux, R | 2 |
| Belrose, G | 3 |
| Gross, A | 1 |
| Olindo, S | 3 |
| Lézin, A | 3 |
| Dueymes, M | 1 |
| Komla-Soukha, I | 1 |
| Smadja, D | 3 |
| Tanaka, Y | 1 |
| Willems, L | 3 |
| Mesnard, JM | 1 |
| Peloponese, JM | 1 |
| Césaire, R | 3 |
| Gillet, N | 2 |
| Rodriguez, S | 1 |
| Boxus, M | 1 |
| Verlaeten, O | 2 |
| Asquith, B | 2 |
| Bangham, C | 1 |
| Signaté, A | 2 |
| Grandvaux, N | 1 |
| de Carvalho Bittencourt, M | 1 |
| Hiscott, J | 1 |
| Burny, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP[NCT00519181] | 19 participants (Actual) | Interventional | 2006-03-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
[Virological aspects of HTLV-1 infection and new therapeutical concepts].
Topics: Animals; Anti-Retroviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Genome, Vir | 2011 |
1 trial available for valproic acid and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
Safety of long-term treatment of HAM/TSP patients with valproic acid.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytophagocytosis; Enzyme Inhibi | 2011 |
3 other studies available for valproic acid and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.
Topics: Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD8-Positive T-Lymphocytes; Deltar | 2010 |
Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes.
Topics: Antisense Elements (Genetics); Apoptosis; Asymptomatic Diseases; Basic-Leucine Zipper Transcription | 2011 |
Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.
Topics: Enzyme Inhibitors; Gene Expression Regulation, Viral; HeLa Cells; Histone Deacetylase Inhibitors; Hi | 2007 |